Matthew Calabrese

Matthew Calabrese has contributed to the clinical translation of PROTAC technology at Arvinas, working on the development and optimization of ARV-471, the oral estrogen receptor PROTAC degrader that has demonstrated clinical efficacy in ER-positive breast cancer. His work on understanding the structure-activity relationships of ER-targeting PROTACs has informed the design of optimized degrader molecules with improved potency and selectivity. He is advancing the development of next-generation PROTACs targeting additional oncology targets based on the clinical validation established by ARV-471.